Neuroblastoma differentiation marker 29 (NDM29) (NDM29)

Neuroblastoma differentiation marker 29 (NDM29) is a long non-coding RNA (lncRNA) transcribed by RNA polymerase III that is primarily expressed in the brain and plays a significant role in regulating cell fate and protein processing (Castelnuovo et al., 2010, Gene). In neuroblastoma, NDM29 acts as a tumor suppressor; its overexpression induces a shift from a highly proliferative, undifferentiated state to a more mature neuronal phenotype, thereby reducing the malignancy of the cells (Pagano et al., 2007, Cancer Research). However, in the context of Alzheimer's disease, NDM29 has been identified as a factor that promotes the generation of neurotoxic amyloid-beta peptides by increasing the synthesis and secretion of the amyloid precursor protein (APP) (Massone et al., 2011, Journal of Biological Chemistry). This dual functionality suggests that NDM29 is a critical regulatory node in both oncology and neurodegeneration. While there are currently no approved drugs targeting NDM29, it is being investigated as a potential site for therapeutic intervention using antisense oligonucleotides or small molecules to modulate its expression levels depending on the disease context.

Other names

NDM29Neuroblastoma differentiation marker 29 non-coding RNAlncRNA NDM29

NDM29 functions as a non-coding RNA that modulates the expression of genes involved in neuronal differentiation and the proteolytic processing of the amyloid precursor protein (APP) (Massone et al., 2011, Journal of Biological Chemistry).